Literature DB >> 7106510

Chronic giardiasis: studies on drug sensitivity, toxin production, and host immune response.

P D Smith, F D Gillin, W M Spira, T E Nash.   

Abstract

UNLABELLED: We investigated a patient (W.B.) with chronic symptomatic Giardiasis despite seven separate courses of either quinacrine or metronidazole who was cured by combined quinacrine and metronidazole. After isolating Giardia lamblia from W.B., we cultured the trophozoites to make the following observations. In vitro drug testing showed that (a) W.B.'s organisms were not more drug resistant than three other isolates and that (b) W.B.'s organisms were more sensitive to combined quinacrine and metronidazole than to either drug alone. Isolates of Giardia lamblia from W.B. and 3 other patients did not produce detectable enterotoxin in four different assays. W.B. had normal levels of circulating immunoglobulins, detectable intestinal immunoglobulin A, circulating immunoglobulin G anti-Giardia lamblia antibodies, and lymphocyte responsiveness to solubilized giardia lamblia. However, monocytes-macrophages from W.B. exhibited reduced killing for Giardia lamblia compared with normal subjects.
CONCLUSIONS: (a) The chronicity of our patient's infection was not due to the organism having unique properties of drug resistance. (b) Combined quinacrine and metronidazole, which cured our patient's chronic giardiasis, should be tried in patients in whom infection persists after single drug therapy. (c) The diarrhea in our patient was probably caused by a mechanism other than Giardia lamblia-induced secretion by currently recognized enterotoxins. (d) Reduced cellular cytotoxicity for Giardia lamblia may have contributed to the persistence of our patient's infection and should be suspected in other patients with chronic giardiasis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7106510

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  51 in total

1.  Variant-specific surface protein switching in Giardia lamblia.

Authors:  T E Nash; H T Luján; M R Mowatt; J T Conrad
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 2.  Biology of Giardia lamblia.

Authors:  R D Adam
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

3.  Optical map of the genotype A1 WB C6 Giardia lamblia genome isolate.

Authors:  D Alexander Perry; Hilary G Morrison; Rodney D Adam
Journal:  Mol Biochem Parasitol       Date:  2011-07-30       Impact factor: 1.759

4.  Modification of RPMI 1640 for use in vitro immunological studies of host-parasite interactions in giardiasis.

Authors:  R A Guy; S Bertrand; G M Faubert
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

Review 5.  Diarrhoea and malabsorption in giardiasis: a multifactorial process?

Authors:  P H Katelaris; M J Farthing
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

6.  Identification and characterization of a major surface antigen of Giardia lamblia.

Authors:  D A Einfeld; H H Stibbs
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

7.  Tubulin and high-molecular-weight polypeptides as Giardia lamblia antigens.

Authors:  B E Torian; R C Barnes; R S Stephens; H H Stibbs
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

8.  Disaccharidase deficiencies in Mongolian gerbils (Meriones unguiculatus) protected against Giardia lamblia.

Authors:  S R Mohammed; G M Faubert
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

9.  Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children.

Authors:  Roberto Canete; Angel A Escobedo; Maria E Gonzalez; Pedro Almirall
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

10.  Cholate-dependent killing of Giardia lamblia by human milk.

Authors:  F D Gillin; D S Reiner; M J Gault
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.